Veloxis Pharmaceuticals Announces Dosing Of The First Patient By Partner Xenikos In The Global Phase 3 Study Evaluating T-Guard® In Patients With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-Agvhd)'

Press/Media

Period28 Jun 2022

Media coverage

1

Media coverage

  • TitleVeloxis Pharmaceuticals Announces Dosing Of The First Patient By Partner Xenikos In The Global Phase 3 Study Evaluating T-Guard® In Patients With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-Agvhd)'
    Media name/outletMENAFN -Press Releases (English)
    Country/TerritoryJordan
    Date28/06/22
    PersonsJohn Levine